timothy sykes logo
BIAF Rises Amid Expansions and Innovations Thumbnail
ADD US ONG Google News

BIAF Rises Amid Expansions and Innovations

MATT MONACO•UPDATED MAR. 20, 2026, 9:18 AM ET
Reviewed by Jack Kellogg Fact-checked by Tim Sykes

bioAffinity Technologies Inc.’s stocks have been trading up by 21.21% fueled by recent strategic partnerships and market optimism.

Candlestick Chart

Live Update At 09:18:06 EDT: On Friday, March 20, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 21.21%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

bioAffinity Technologies reported a record-breaking revenue in 2025, marked by an impressive 87% increase in their CyPath Lung diagnostic sales, along with a 99% surge in test volumes. While these numbers are exciting, the bottom line shows a deeper narrative. Consolidated revenue, unfortunately, suffered a decline due to the closure of unprofitable pathology services. Losses widened to an unexpected $14.9M as the business leaned heavily on the commercialization of a core product. The company also raised $16.9M to bolster liquidity and support their aggressive growth, yet there is still reliance on capital markets for sustenance.

Looking at the company’s other financial metrics, their recent earnings show nuanced insights. Total assets and cash equivalents speak to a sturdy position; however, negative key ratios such as pre-tax profit margin reflect challenges in profitability. The current ratio remains strong, hinting at an ability to meet short-term obligations. EBITDA, being in the negatives, signals caution in assessing core earnings power. Overall, BIAF is facing both opportunities and hurdles as it maneuvers through economic complexities while striving to make healthcare innovations.

Market Reactions to Recent Developments

The latest results from BIAF sparked mixed reactions in the market. Investors found comfort in the notable record-breaking internal growth figures. The CyPath Lung diagnostic is performing well, and the positive reception in the medical community helps to create a promising backdrop. Moreover, the announcement of a 2,000-patient multi-site clinical study aims to offer breakthroughs in early lung cancer diagnosis. This can potentially position BIAF as a pivotal player in the lung cancer diagnostics industry. Expansion of partnerships with VA and military health systems represents a confident step in expanding influence. However, the transactional aspects of financials reveal a different tale. Losses hint at costly aspects of growth, likely affecting short-term investor sentiments.

Despite these challenges, expectations for 2026 remain optimistic, labeling further unit growth over 100%. BIAF will need to balance spending to maintain progressiveness without straining available resources. The company’s current strategy underscores the importance of communication with shareholders, as detailed in the recent report, and aims to clearly outline plans for returning to profitability while strengthening advocacy for their medical technologies.

More Breaking News

Conclusion

bioAffinity Technologies looks set for an exciting, albeit challenging path. Economic pressures require smart navigating to ensure the core products meet market expectations and profitability demands. As BIAF moves toward new horizons in healthcare innovation, their ability to manage expenditure while preserving growth and expanding their footprint remains critical in defining their stock value. As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.” This mindset will be crucial for BIAF as they approach the weeks ahead, determining how the stock maneuvers as both internal and external factors play pivotal roles in shaping the outcome. Strategically balanced between risks and opportunities, BIAF’s performance in the upcoming quarter may determine the future pricing trajectory and trader sentiment.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BIAF

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”